Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhenium Re 188 P2045 in lung cancer
NCT00100256Phase 2Unknown
- Sponsor
- Andarix Pharmaceuticals
- Start
- Jan 2004
- Primary completion
- Jun 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 188Re-P2045 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), sponsored by Andarix Pharmaceuticals. Primary endpoints: Maximum tolerated dose of Rhenium 188 P2045 at 1 month, Safety of Technetium Tc 99m P2045 and Rhenium Re 188 P2045 at 1 year and 1 more. Status: unknown.
02
Drugs
188Re-P2045
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00100256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100256.